Onconova Therapeutics Inc (NASDAQ:ONTX) posted its quarterly earnings results on Monday. The company reported ($0.87) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.78) by $0.09, Stock Ratings Network.com reports. Onconova Therapeutics Inc (NASDAQ:ONTX) weekly performance is -8.73%. On last trading day company shares ended up $5.02. Analysts mean target price for the company is $11.50. Onconova Therapeutics Inc (NASDAQ:ONTX) distance from 50-day simple moving average (SMA50) is -21.80%.
Biota Pharmaceuticals Inc (NASDAQ:BOTA) in a press release announced that the company would no longer provide services of developing Laninamivir octanoate, to the government’s Biomedical Advanced Research and Development Authority (BARDA) and the Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response (ASPR). Biota Pharmaceuticals Inc (NASDAQ:BOTA) shares fell -2.08% in last trading session and ended the day on $2.82. BOTA Gross Margin is 35.60% and its return on assets is -12.10%. Biota Pharmaceuticals Inc (NASDAQ:BOTA) quarterly performance is -46.69%.
On May 12, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted its quarterly earnings results on Monday. The company reported ($0.85) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $0.48, American Banking and Market Newsreports. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares moved down -1.76% in last trading session and was closed at $33.44, while trading in range of $33.02 – $34.22. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) year to date (YTD) performance is -20.85%.
On May 5, Cleveland BioLabs, Inc. (NASDAQ:CBLI) reported financial results and development progress for the first quarter ended March 31, 2014. Cleveland BioLabs reported a net loss for the first quarter of 2014 of $1.9 million, or $0.03 per share, which represents an improvement of $8.9 million as compared to the first quarter of 2013. $5.5 million of this improvement was due to a non-cash change in the fair market valuation of certain outstanding warrants, with the remaining $3.4 million of this improvement, due to a reduction in operating losses. The reduced operating losses were due to a narrowed focus of development activities, lower development costs for Entolimod as a radiation countermeasure and other cost saving measures. Cleveland BioLabs, Inc. (NASDAQ:CBLI) ended the last trading day at $0.545. Company weekly volatility is calculated as 8.02% and price to cash ratio as 2.72. Cleveland BioLabs, Inc. (NASDAQ:CBLI) showed a negative weekly performance of -5.17%.
On May 5, Heat Biologics, Inc. (NASDAQ:HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced its financial results for the first quarter ended March 31, 2014 and provided highlights of the Company’s recent corporate progress and anticipated near-term milestones for its two lead product candidates, HS-110(Viagenpumatucel-L) for the treatment of non-small cell lung cancer (NSCLC) and HS-410(Vesigenurtacel-L) for the treatment of bladder cancer. For the first quarter ended March 31, 2014, Heat Biologics reported a net loss of ($2,422,966), and a net loss attributable to common stockholders of ($2,330,597) or ($0.36) per share as compared to a net loss of ($788,461) and a net loss attributable to common stockholders of ($3,063,856), or ($1.66) per share for the first quarter ended March 31, 2013. Heat Biologics Inc (NASDAQ:HTBX) weekly performance is -17.12%. On last trading day company shares ended up $3.97. Analysts mean target price for the company is $27.00. Heat Biologics Inc (NASDAQ:HTBX) distance from 50-day simple moving average (SMA50) is -34.28%.